Buy Lexapro Online

30 pills x 5mg	$21.14	only $0.7 per pill	Buy Lexapro
60 pills x 5mg	$36.21	only $0.61 per pill	Buy Lexapro
90 pills x 5mg	$45.11	only $0.5 per pill	Buy Lexapro
30 pills x 10mg	$37.82	only $1.26 per pill	Buy Lexapro
60 pills x 10mg	$64.79	only $1.08 per pill	Buy Lexapro
90 pills x 10mg	$81.14	only $0.9 per pill	Buy Lexapro
30 pills x 20mg	$52.51	only $1.75 per pill	Buy Lexapro
60 pills x 20mg	$90.14	only $1.5 per pill	Buy Lexapro
90 pills x 20mg	$112.49	only $1.25 per pill	Buy Lexapro

WARNINGS LEXAPRO (Escitalopram)

POTENTIAL FOR INTERACTION WITH MONOAMINE OXIDASE INHIBITORS

In patients receiving serotonin reuptake inhibitor drugs in combination with a monoamine oxidase inhibitor (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma. These reactions have also been reported in patients who have recently discontinued SSRI treatment and have been started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Furthermore, limited animal data on the effects of combined use of SSRIs and MAOIs suggest that these drugs may act synergistically to elevate blood pressure and evoke behavioral excitation. Therefore, it is recommended that LEXAPRO should not be used in combination with an MAOI, or within 14 days of discontinuing treatment with an MAOI. Similarly, at least 14 days should be allowed after stopping LEXAPRO before starting an MAOI.

Serotonin syndrome has been reported in two patients who were concomitantly receiving linezolid, an antibiotic which is a reversible non-selective MAOI.

CLINICAL WORSENING AND SUICIDE RISK

Patients with major depressive disorder, both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality), whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs.

Although there has been a long-standing concern that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients, a causal role for antidepressants in inducing such behaviors has not been established. Nevertheless, patients being treated with antidepressants should be observed closely for clinical worsening and suicidality, especially at the beginning of a course of drug therapy, or at the time of dose changes, either increases or decreases. Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse or whose emergent suicidality is severe, abrupt in onset, or was not part of the patient's presenting symptoms.

Because of the possibility of co-morbidity between major depressive disorder and other psychiatric and nonpsychiatric disorders, the same precautions observed when treating patients with major depressive disorder should be observed when treating patients with other psychiatric and nonpsychiatric disorders.

The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility (aggressiveness), impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients for whom such symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms.

Families and caregivers of patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to healthcare providers. Prescriptions for LEXAPRO should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose.

If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms (see PRECAUTIONS and DOSAGE AND ADMINISTRATION, Discontinuation of Treatment with LEXAPRO, for a description of the risks of discontinuation of LEXAPRO).

It should be noted that LEXAPRO is not approved for use in treating any indications in the pediatric population.

A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. It should be noted that LEXAPRO is not approved for use in treating bipolar depression.

A head-to-head trial was conducted to compare Lexapro and Paxil®PAXIL is a medicine used to treat depression, panic disorder, social anxiety disorder, and premenstrual dysphoric disorder. Paxil is a selective serotonin reuptake inhibitor (SSRI) that treats the symptoms of these conditions by restoring the balance of serotonin in the brain. (paroxetine HCL) in the treatment of GAD. In this trial, patients taking Lexapro and patients taking Paxil® experienced improvement of their GAD symptoms. However, fewer patients stopped taking Lexapro due to side effects as compared to patients taking Paxil® (7% for Lexapro vs 23% for Paxil®).

In addition, in this trial, clinically significant weight gain occurred less often in patients treated with Lexapro over 24 weeks (8% for Lexapro vs 18% for Paxil®).

Full antidepressant/anxiolytic effect may take 4 to 6 weeks.

8% for Lexapro vs 4% for placebo in the comprehensive GAD safety database.